Experts assumed China needed an mRNA COVID vaccine to reopen safely. New data suggest that may not be the caseRead Now
China’s inactivated Sinovac COVID vaccine may provide as much protection from death as Germany’s BioNTech mRNA jab after three doses, according to new research from Hong Kong University. The findings suggest that China, which continues to impose tough COVID-zero policies, may not need to approve or develop mRNA vaccines to emerge from the pandemic.
Hong Kong Free Press announced:
During the press conference, HKU’s medical faculty released its latest empirical analysis of the effectiveness of the two available vaccines – the Chinese-made Sinovac and German-produced BioNTech – based on data of hospitalised patients in Hong Kong as of March 8.
According to their findings, receiving three jabs of a Covid-19 vaccine, irrespective of the brand, can provide around 98 per cent of immunity against severe or fatal cases in patients aged 60 or above.
Artificial intelligence can improve medical imaging for screenings, precision medicine, and risk assessment.